In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Assembly Biosciences Inc. (NASDAQ:ASMB) reported that Acuta Capital Partners, Llc has picked up 986,599 of common stock as of 2017-08-03.
The acquisition brings the aggregate amount owned by Acuta Capital Partners, Llc to a total of 986,599 representing a 5.7% in the company.
For those not familiar with the company, Assembly Biosciences, Inc. is a biotechnology company. The Company is engaged in developing two platform programs, such as a class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection, and a class of oral synthetic live therapeutics, which are designed to restore health to a dysbiotic microbiome. It has discovered various core protein Allosteric Modulators (CpAMs), which are small molecules that directly target and allosterically modulate the HBV core (HBc) protein.
A glance at Assembly Biosciences Inc. (NASDAQ:ASMB)’s key stats reveals a current market capitalization of 387.69M based on 17.35M shares outstanding and a price at last close of $22.35 per share.
Looking at insider activity, there are a few recent transactions worth noting.
Specifically, on 2016-02-11, Small picked up 1,555 at a purchase price of $5.56 per share.This brings their total holding to 634,391 as of the date of the filing.
On the sell side, the most recent transaction saw Ringo unload 3,461 shares at a sale price of $22.00. This brings their total holding to 0.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Assembly Biosciences Inc. (NASDAQ:ASMB) as things move forward to see if its progress aligns with these transactions. Subscribe below and we’ll keep you on top of what’s happening before it moves markets.